A detailed history of Gsa Capital Partners LLP transactions in Allakos Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 794,896 shares of ALLK stock, worth $937,977. This represents 0.04% of its overall portfolio holdings.

Number of Shares
794,896
Previous 710,146 11.93%
Holding current value
$937,977
Previous $710,000 26.9%
% of portfolio
0.04%
Previous 0.05%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$0.54 - $0.92 $45,765 - $77,970
84,750 Added 11.93%
794,896 $519,000
Q2 2024

Aug 15, 2024

SELL
$1.0 - $1.45 $27,177 - $39,406
-27,177 Reduced 3.69%
710,146 $710,000
Q1 2024

May 03, 2024

BUY
$1.02 - $3.23 $752,069 - $2.38 Million
737,323 New
737,323 $929,000
Q2 2023

Aug 14, 2023

BUY
$3.6 - $5.25 $304,992 - $444,780
84,720 New
84,720 $369,000
Q2 2022

Aug 09, 2022

BUY
$2.6 - $6.14 $68,855 - $162,605
26,483 New
26,483 $83,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $100M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.